MON, MAY 31ST, 2021 08:00 CET

ChloraSolv is regulatory approved in Kuwait for diabetic foot ulcers

RLS Global AB has received regulatory approval for ChloraSolv regarding the treatment of diabetic foot ulcers in Kuwait. With this approval, RLS has established the first market presence in the Middle East, which is an important region for RLS. The prevalence of diabetes in the Middle East is very high and is expected to increase until 2045 according to the International Diabetes Federation*. In Kuwait, the prevalence in the population is 12,2 percent compared to 4,5 percent in Sweden.

Kuwait is the first step in establishing RLS’ presence in the Middle East. RLS has established a partnership with a local distributor active in the medical device business. During the registration process, the distributor has built up an important network of clinics that have interest and need for ChloraSolv, and the commercial launch did start in connection with the approval. In parallel, the RLS distributor will apply for an extended indication for ChloraSolv (leg ulcers) in Kuwait which is expected in about five months.

”The Middle East is an interesting region for RLS as diabetes is increasing at an accelerating pace. ChloraSolv, with its unique attributes, will help many patients who get foot ulcers due to diabetes. Also, the healthcare costs are very high for this patient group. It is gratifying that we have several clinics in Kuwait ready to start treating patients with ChloraSolv”, says Karin Fischer, CEO of RLS Global.

* International Diabetes Federation. IDF Diabetes Atlas, 9th edn. Brussels, Belgium: 2019


RLS Global’s shares have been listed on the Nasdaq First North Growth Market since 17th May, 2017 and trading takes place under the short name RLS. Certified Adviser is Redeye Aktiebolag.
phone: +46 8 121 576 90, email:
During the period 2012–2017, the company was listed on Aktietorget.


Karin Fischer, CEO
Telephone: +46 702-48 46 51

Anders Husmark, CBDO RLS Global AB
Telephone: +46 724-50 94 03


About RLS Global AB
RLS Global AB is a medical technology company within Life Science. Based on the company’s unique hypochlorite platform, RLS Global develop products for some of our most common illnesses in wound and oral care. RLS Global has a portfolio of strong brands, including ChloraSolv® and Carisolv®. The company is listed on Nasdaq First North with Redeye Aktiebolag, phone: +46 8 121 576 90, email: Read more at